NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
Clinical Trials
11 trialsNCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05245760 2022-11-08
CRATER
University of Kentucky
Phase 2 Withdrawn
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT00226746 2020-09-18
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
New York Presbyterian Brooklyn Methodist Hospital
Phase 2 Withdrawn
NCT03704077 2020-05-19
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03766607 2019-09-19
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Korean South West Oncology Group
Phase 2 Withdrawn
NCT02274012 2017-03-14
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Columbia University
Phase 2 Withdrawn
NCT02598687 2016-04-21
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Maastricht Radiation Oncology
Phase 1 Withdrawn
NCT00209612 2009-02-17
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Withdrawn